Lyncbio
1 known investors
Lync Bio develops fourth-generation SMART ADC (antibody-drug conjugate) technology for oncology, leveraging proprietary dual-target conjugate design and payload engineering to improve tumor coverage, cellular response, and manufacturability.
Investors · 1
Frequently asked questions
- What does Lyncbio do?
- Lync Bio develops fourth-generation SMART ADC (antibody-drug conjugate) technology for oncology, leveraging proprietary dual-target conjugate design and payload engineering to improve tumor coverage, cellular response, and manufacturability.
- Who are Lyncbio's investors?
- Lyncbio's investors include Pan-Lin Capital.